Cargando…
Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS
BACKGROUND: Pancreatic enzyme-replacement therapy (PERT), provided as pancreatin to patients with pancreatic exocrine insufficiency (PEI), is considered an essential substitute for the pivotal physiological function the pancreas fulfills in digestion. PEI involves a reduction in the synthesis and se...
Autores principales: | Maev, Igor V., Kucheryavyy, Yury A., Gubergrits, Natalya B., Bonnacker, Ingo, Shelest, Ekaterina A., Janssen-van Solingen, Gwendolyn P., Domínguez-Muñoz, J. Enrique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691409/ https://www.ncbi.nlm.nih.gov/pubmed/33211277 http://dx.doi.org/10.1007/s40268-020-00326-z |
Ejemplares similares
-
Author’s Reply to Petersen: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”
por: Maev, Igor V., et al.
Publicado: (2021) -
Comment on: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”
por: Petersen, Karl-Uwe
Publicado: (2021) -
Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency
por: Layer, Peter, et al.
Publicado: (2019) -
Note on Pancreatin
por: Mattison, Richard V.
Publicado: (1873) -
Combined Solution of Pepsine and Pancreatine
Publicado: (1871)